search
Back to results

The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal

Primary Purpose

Penicillin Allergy

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Penicillin Allergic Risk Stratification Best Practice Alert
Sponsored by
Vanderbilt University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Penicillin Allergy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • VUMC patients age 18 or older with a penicillin allergy reported in their chart, and are medically stable, currently admitted to stepdown unit or regular floor bed.

Exclusion Criteria:

  • Patients with a penicillin allergy reported in their chart, but who are currently medically unstable.
  • Pregnant patients

Sites / Locations

  • Vanderbilt University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Penicillin Allergic Floor Patients- Experimental

Penicillin Allergic Floor Patients- Control

Arm Description

The intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk.

Patients will receive current standard of care for penicillin allergy, which typically involves physician judgement on challenges versus consultation of allergy service.

Outcomes

Primary Outcome Measures

Penicillin allergy label removal
The proportion of patients with low risk penicillin allergy whose labels are removed from the medical chart's allergy section.
Patients with low risk penicillin allergy label who underwent amoxicillin challenge
The proportion of patients with low risk penicillin allergy who underwent amoxicillin challenge

Secondary Outcome Measures

Adverse events (in particular, reported allergic events)
The proportion of penicillin allergic patients challenged with amoxicillin who reported adverse events
Communication about penicillin allergy in discharge summary
The proportion of penicillin allergic patients whose discharge summary contains information about penicillin allergy at discharge.
Antibiotic utilization by patients
The number of changes or new starts of penicillin or cephalosporin treatments as a result of penicillin allergy label removal and the proportion of patients experiencing this event, this will be looked at as "Same hospitalization" as the challenge or "Subsequent Utilization"
Durability of penicillin allergy label removal
The proportion of penicillin allergic patients whose penicillin allergy labels were removed at discharge whose labels are not reentered into the chart.
Tolerance of amoxicillin challenge
Any adverse events reported in association with amoxicillin challenge
Uptake of the risk stratification tool
Determined by whether patients with a penicillin allergy label received a risk assessment
Time to penicillin allergy label return
For those patients who underwent a penicillin allergy label removal and it returns, we will compare the date the allergy label returned with the date it was removed

Full Information

First Posted
October 8, 2018
Last Updated
July 21, 2023
Sponsor
Vanderbilt University Medical Center
Collaborators
Vanderbilt Institute for Clinical and Translational Research (Learning Healthcare System)
search

1. Study Identification

Unique Protocol Identification Number
NCT03702270
Brief Title
The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal
Official Title
The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
November 11, 2020 (Actual)
Primary Completion Date
December 11, 2021 (Actual)
Study Completion Date
May 11, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University Medical Center
Collaborators
Vanderbilt Institute for Clinical and Translational Research (Learning Healthcare System)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Currently it is estimated that at least 25 million people in the United States are labeled as penicillin allergic although less than 1.5 million of these are truly allergic. Although combined skin testing and oral challenge is an evidence-based de-labeling strategy the high burden of penicillin allergy labels means these services are available only through specialty allergy practices. There is therefore a need to provide evidence for alternative penicillin de-labeling strategies such as direct oral challenge. Previous studies have utilized quasi-experimental designs. Test dose challenges are currently recommended as a strategy for removal of low risk drug allergies, but the current experience is limited to single arm observational studies and evidence-based strategies for identifying low risk patients are lacking. Our objective is to demonstrate the benefit of providing risk stratification in removing penicillin allergy labels for low risk penicillin allergy patients in a randomized controlled trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Penicillin Allergy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
During the trial, randomization will occur using a stepped wedge cluster randomized controlled trial design. Medical units at VUMC will assigned to clusters. A single cluster will be selected for intervention at the outset of the trial. Subsequent additional clusters will first contribute to the control group, and be selected to randomly cross over to the intervention group at regular intervals of 1 months.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2040 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Penicillin Allergic Floor Patients- Experimental
Arm Type
Experimental
Arm Description
The intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk.
Arm Title
Penicillin Allergic Floor Patients- Control
Arm Type
No Intervention
Arm Description
Patients will receive current standard of care for penicillin allergy, which typically involves physician judgement on challenges versus consultation of allergy service.
Intervention Type
Other
Intervention Name(s)
Penicillin Allergic Risk Stratification Best Practice Alert
Intervention Description
Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
Primary Outcome Measure Information:
Title
Penicillin allergy label removal
Description
The proportion of patients with low risk penicillin allergy whose labels are removed from the medical chart's allergy section.
Time Frame
Hospital discharge at approximately 4 days after admission
Title
Patients with low risk penicillin allergy label who underwent amoxicillin challenge
Description
The proportion of patients with low risk penicillin allergy who underwent amoxicillin challenge
Time Frame
Hospital discharge at approximately 4 days after admission
Secondary Outcome Measure Information:
Title
Adverse events (in particular, reported allergic events)
Description
The proportion of penicillin allergic patients challenged with amoxicillin who reported adverse events
Time Frame
Hospital discharge at approximately 4 days after admission
Title
Communication about penicillin allergy in discharge summary
Description
The proportion of penicillin allergic patients whose discharge summary contains information about penicillin allergy at discharge.
Time Frame
Hospital discharge at approximately 4 days after admission
Title
Antibiotic utilization by patients
Description
The number of changes or new starts of penicillin or cephalosporin treatments as a result of penicillin allergy label removal and the proportion of patients experiencing this event, this will be looked at as "Same hospitalization" as the challenge or "Subsequent Utilization"
Time Frame
Hospital discharge at approximately 4 days after admission and from 3-18 months of follow up
Title
Durability of penicillin allergy label removal
Description
The proportion of penicillin allergic patients whose penicillin allergy labels were removed at discharge whose labels are not reentered into the chart.
Time Frame
Hospital discharge at approximately 4 days after admission and from 3-18 months of follow up
Title
Tolerance of amoxicillin challenge
Description
Any adverse events reported in association with amoxicillin challenge
Time Frame
Within 24 hours of the amoxicillin challenge
Title
Uptake of the risk stratification tool
Description
Determined by whether patients with a penicillin allergy label received a risk assessment
Time Frame
Hospital discharge at approximately 4 days after admission
Title
Time to penicillin allergy label return
Description
For those patients who underwent a penicillin allergy label removal and it returns, we will compare the date the allergy label returned with the date it was removed
Time Frame
From 3-18 months of follow up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: VUMC patients age 18 or older with a penicillin allergy reported in their chart, and are medically stable, currently admitted to stepdown unit or regular floor bed. Exclusion Criteria: Patients with a penicillin allergy reported in their chart, but who are currently medically unstable. Pregnant patients
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cosby Stone, MD, MPH
Organizational Affiliation
Vanderbilt University Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Chris Lindsell, PhD
Organizational Affiliation
Vanderbilt University Medical Center
Official's Role
Study Chair
Facility Information:
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal

We'll reach out to this number within 24 hrs